基于全反钴胺素的算法识别分析性高钴胺素血症中的大分子维生素B12
该研究收集528例成人血清,用商业免疫分析法测总B12和全反钴胺素(HoloTC),以聚乙二醇沉淀后B12回收率<50%定义大分子B12(M-B12)。高钴胺素血症样本中16.0%(66/411)检出M-B12,正常钴胺素血症样本无一例。HoloTC在高钴胺素血症中受M-B12影响,以201 pmol/L为切点识别M-B12的AUC为0.870,灵敏度75.0%、特异度95.1%。
要点
- 高钴胺素血症样本中M-B12检出率16.0%(66/411),正常样本未检出。
- M-B12组HoloTC中位数300 pmol/L,高于无M-B12高钴胺素血症组的120 pmol/L。
- HoloTC以201 pmol/L识别M-B12的AUC为0.870,灵敏度75.0%、特异度95.1%。
核心结论
- HoloTC浓度受B12大分子复合物存在的影响。
- HoloTC检测可作为筛查分析性高钴胺素血症患者中M-B12的生物标志物。
研究设计与样本
- 收集528例成人血清样本,用商业免疫分析法测总B12和HoloTC。
- 以聚乙二醇沉淀后B12回收率<50%定义M-B12存在。
主要发现
- 高钴胺素血症样本中M-B12检出率为16.0%(66/411),正常钴胺素血症样本中无一例检出。
- 3例M-B12样本经PEG沉淀后B12低于参考下限。
- 正常钴胺素血症组B12回收率高于无M-B12高钴胺素血症组(p < 0.001)。
- HoloTC亚组中,M-B12组中位数300 pmol/L高于无M-B12高钴胺素血症组的120 pmol/L,正常钴胺素血症组与无M-B12高钴胺素血症组无差异。
- 高钴胺素血症样本PEG沉淀后HoloTC回收率低于B12回收率(无M-B12组:29.8% vs 73.1%;M-B12组:11.0% vs 27.5%),正常钴胺素血症组差异不显著(62.9% vs 83.5%)。
关键数值与推荐
- M-B12定义:聚乙二醇沉淀后B12回收率<50%。
- HoloTC识别M-B12的切点201 pmol/L,AUC 0.870,灵敏度75.0%,特异度95.1%。
临床怎么用
- 遇意外高钴胺素血症时,应考虑B12大分子复合物干扰,可用HoloTC辅助筛查M-B12。
- HoloTC结果解释需注意M-B12的存在可能使其升高。
局限性
- HoloTC仅在亚组样本中检测(正常钴胺素血症n=16;无M-B12高钴胺素血症n=41;M-B12高钴胺素血症n=40)。
- M-B12影响HoloTC免疫分析性能的机制尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Interference by vitamin B12 (B12) macrocomplexes is common but underappreciated in clinical practice. When unexpected hypercobalaminemia is detected, analytical interference must be considered. Holotranscobalamin (HoloTC) reflects the biologically active B12 fraction, but the impact of B12 macrocomplexes (M-B12) on HoloTC immunoassay performance remains unclear. METHODS: We collected 528 adult serum samples. Total B12 and HoloTC were measured by commercial immunoassays. M-B12 presence was defined as B12 recovery after polyethylene glycol precipitation (PEG) <50%. RESULTS: Samples were classified as HyperB12 (hypercobalaminemia) or NormoB12. M-B12 was detected in 16.0% (66/411) of HyperB12 samples but in none of NormoB12. In three M-B12 cases, B12 fell below the lower reference limit after PEG. B12 recovery was higher in NormoB12 than in NoM-HyperB12 (p < 0.001). HoloTC was measured in a subgroup of samples (NormoB12 n = 16; NoM-HyperB12 n = 41; M-HyperB12 n = 40). HoloTC was higher in M-HyperB12 (median 300 pmol/L) than in NoM-HyperB12 (median 120 pmol/L), while NormoB12 did not differ from NoM-HyperB12. After PEG precipitation, HoloTC recovery was lower than B12 recovery in HyperB12 samples (NoM-HyperB12: 29.8% vs 73.1%; M-HyperB12: 11.0% vs 27.5%), whereas the difference was not significant in NormoB12 (62.9% vs 83.5%). B12 and HoloTC concentrations showed correlation before (r = 0.45, p = 0.004) and after PEG (r = 0.52, p < 0.001) precipitation only in M-B12 group. HoloTC identified M-B12 presence (AUC 0.870) with 75.0% sensitivity and 95.1% specificity at 201 pmol/L. CONCLUSION: HoloTC concentrations are influenced by the presence of B12 macrocomplexes. The HoloTC assay may serve as a biomarker to screen for M-B12 in patients with analytical HyperB12.
引用
- Fernández-Tomás P, Ruiz L, Alegre E, et al. Holotranscobalamin-based algorithm for the identification of macro-vitamin B12 in analytical hypercobalaminemia. Clin Chim Acta. 2026. PMID: 42142694. doi:10.1016/j.cca.2026.121085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。